Search

Your search keyword '"Giacomelli, R"' showing total 1,653 results
Start Over Author "Giacomelli, R"
1,653 results on '"Giacomelli, R"'

2. AB0713 PAIN CATASTROPHIZING AND ITS DOMAINS HELPLESSNESS AND RUMINATION IMPACT SIGNIFICANTLY ON DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS: DATA FROM A MULTICENTER ITALIAN STUDY

Author

Kun, L., primary, Currado, D., additional, Berardicurti, O., additional, Vomero, M., additional, Marino, A., additional, Biaggi, A., additional, Pilato, A., additional, Corberi, E., additional, Trunfio, F., additional, Orlando, A., additional, Quadrini, M., additional, Saracino, F., additional, Lamberti, L., additional, Navarini, L., additional, and Giacomelli, R., additional

Published
2024
Full Text
View/download PDF

3. POS1247 CHARACTERIZATION OF 284 PATIENTS PRESENTING WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OF SJÖGREN DISEASE: RESULTS FROM THE SJÖGREN BIG DATA REGISTRY

Author

Alunno, A., primary, Brito-Zerón, P., additional, Carubbi, F., additional, Ng, W. F., additional, Flores-Chávez, A., additional, Szántó, A., additional, Li, X., additional, Rasmussen, A., additional, Dong, X., additional, Priori, R., additional, Olsson, P., additional, Baldini, C., additional, Seror, R., additional, Bootsma, H., additional, Armagan, B., additional, Kaya, B., additional, Gottenberg, J. E., additional, Praprotnik, S., additional, Suzuki, Y., additional, Quartuccio, L., additional, Leavis, H., additional, Hernandez-Molina, G., additional, Inanc, N., additional, Danda, D., additional, Bartoloni, E., additional, Rischmueller, M., additional, Sebastian, A., additional, Silvério-António, M., additional, Reis de Oliveira, F., additional, Kwok, S. K., additional, Kvarnstrom, M., additional, Solans-Laqué, R., additional, Fernandes Moça Trevisani, V., additional, Galisteo, C., additional, Sene, D., additional, Jurcut, C., additional, Fugmann, C., additional, Hofauer, B., additional, Isenberg, D., additional, Atzeni, F., additional, Shimuzu, T., additional, Valim, V., additional, Pasoto, S., additional, González García, A., additional, Retamozo, S., additional, Cipriani, P., additional, Devauchelle-Pensec, V., additional, Melchor Díaz, S., additional, Gheita, T. A., additional, Morcillo, C., additional, Fonseca-Aizpuru, E., additional, Lopez-Dupla, J. M., additional, Giacomelli, R., additional, Nakamura, H., additional, Vázquez, M., additional, Morel, J., additional, Consani-Fernández, S., additional, Akasbi Montalvo, M., additional, Diaz Cuiza, P. E., additional, De Miguel-Campo, B., additional, Lee, A. Y. S., additional, and Ramos-Casals, M., additional

Published
2024
Full Text
View/download PDF

5. POS1148 MECHANISMS OF PAIN MODULATION BY JAK INHIBITION: UPADACITINIB REGULATES PAIN-RELATED PATHWAYS AND BDNF EXPRESSION IN MICROGLIAL CELLS

Author

Navarini, L., primary, Vomero, M., additional, Corberi, E., additional, Berardicurti, O., additional, Imperatori, G., additional, Currado, D., additional, Kun, L., additional, Trunfio, F., additional, Saracino, F., additional, Lamberti, L., additional, Marino, A., additional, La Barbera, L., additional, Krashia, P., additional, D’amelio, M., additional, and Giacomelli, R., additional

Published
2024
Full Text
View/download PDF

6. POS0854 HOPELESSNESS LEVELS ARE SIGNIFICANTLY INCREASED IN SYSTEMIC SCLEROSIS PATIENTS AND CORRELATE WITH THE RAYNAUD CONDITION SCORE AND DIGITAL ULCER SEVERITY

Author

Bearzi, P., primary, Minerba, M., additional, Salvolini, C., additional, Quarta, L., additional, Lanaia, G., additional, Currado, D., additional, Marino, A., additional, Corberi, E., additional, Cocchiaro, T., additional, Vizzini, M., additional, Vomero, M., additional, Berardicurti, O., additional, Marcoccia, A., additional, Navarini, L., additional, and Giacomelli, R., additional

Published
2024
Full Text
View/download PDF

7. The NESSiE Concept for Sterile Neutrinos

Author

Stanco, L., Anokhina, A., Bagulya, A., Benettoni, M., Bernardini, P., Bertolin, A., Brugnera, R., Calabrese, M., Cecchetti, A., Cecchini, S., Chernyavskiy, M., Collazuol, G., Creti, P., Corso, F. Dal, Dalkarov, O., Del Prete, A., De Mitri, I., De Robertis, G., De Serio, M., Esposti, L. Degli, Di Ferdinando, D., Dore, U., Dusini, S., Dzhatdoev, T., Fanin, C., Fini, R. A., Fiore, G., Galati, G., Garfagnini, A., Giacomelli, G., Giacomelli, R., Golovanov, S., Guandalin, C., Guerzoni, M., Klicek, B., Kose, U., Jakovcic, K., Laurenti, G., Laveder, M., Lippi, I., Loddo, F., Longhin, A., Loverre, P., Malenica, M., Mancarella, G., Mandrioli, G., Margiotta, A., Marsella, G., Mauri, N., Medinaceli, E., Mengucci, A., Mezzetto, M., Michinelli, R., Mingazheva, R., Morgunova, O., Muciaccia, M. T., Orecchini, D., Paoloni, A., Papadia, G., Paparella, L., Pastore, A., Patrizii, L., Polukhina, N., Pozzato, M., Roda, M., Roganova, T., Rosa, G., Sahnoun, Z., Simone, S., Sioli, M., Sirignano, C., Sirri, G., Spurio, M., Starkov, N., Stipcevic, M., Surdo, A., Tenti, M., Togo, V., Ventura, M., Vladymyrov, M., and Zago, M.

Subjects
High Energy Physics - Phenomenology, Physics - Instrumentation and Detectors
Abstract

Neutrino physics is nowadays receiving more and more attention as a possible source of information for the long-standing problem of new physics beyond the Standard Model. The recent measurement of the third mixing angle theta13 in the standard mixing oscillation scenario encourages us to pursue the still missing results on leptonic CP violation and absolute neutrino masses. However, several puzzling measurements exist, which deserve an exhaustive evaluation. The NESSiE Collaboration has been setup to undertake a definitive experiment to clarify the muon disappearance measurements at small L/E, which will be able to put severe constraints to any model with more than the three-standard neutrinos, or even to robustly measure the presence of a new kind of neutrino oscillation for the first time. Within the context of the current CERN project, aimed to revitalize the neutrino field in Europe, we will illustrate the achievements that can be obtained by a double muon-spectrometer system, with emphasis on the search for sterile neutrinos., Comment: 13 pages, Proceedings of XV Workshop on Neutrino Telescopes, 11-15 March 2013, Venice, Italy

Published
2013

8. The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry

Author

362., Ruscitti P, Sota, J, Vitale, A, Lopalco, G, Iannone, F, Morrone, M, Giardini, Ham, D'Agostin, Ma, Antonelli, Ipb, Almaghlouth, I, Asfina, Kn, Khalil, N, Sfikakis, Pp, Laskari, K, Tektonidou, M, Ciccia, F, Iacono, D, Riccio, F, Ragab, G, Hussein, Ma, Govoni, M, Ruffilli, F, Direskeneli, H, Alibaz-Oner, F, Giacomelli, R, Navarini, L, Bartoloni, E, Riccucci, I, Martín-Nares, E, Torres-Ruiz, J, Cipriani, P, Di Cola, I, Hernández-Rodríguez, J, Gómez-Caverzaschi, V, Dagna, L, Tomelleri, A, Makowska, J, Brzezinska, O, Iagnocco, A, Bellis, E, Caggiano, V, Gaggiano, C, Tarsia, M, Mormile, I, Emmi, G, Sfriso, P, Monti, S, Erten, Ş, Del Giudice, E, Lubrano, R, Conti, G, Olivieri, An, Lo Gullo, A, Tharwat, S, Karamanakos, A, Gidaro, A, Maggio, Mc, La Torre, F, Cardinale, F, Ogunjimi, B, Maier, A, Sebastiani, Gd, Opris-Belinski, D, Frassi, M, Viapiana, O, Bizzi, E, Carubbi, F, Fotis, L, Tufan, A, Kardas, Rc, Więsik-Szewczyk, E, Jahnz-Różyk, K, Fabiani, C, Frediani, B, Balistreri, A, Rigante, Donato, Cantarini, L, 362. Ruscitti P, Sota J, Vitale A, Lopalco G, Iannone F, Morrone M, Giardini HAM, D'Agostin MA, Antonelli IPB, Almaghlouth I, Asfina KN, Khalil N, Sfikakis PP, Laskari K, Tektonidou M, Ciccia F, Iacono D, Riccio F, Ragab G, Hussein MA, Govoni M, Ruffilli F, Direskeneli H, Alibaz-Oner F, Giacomelli R, Navarini L, Bartoloni E, Riccucci I, Martín-Nares E, Torres-Ruiz J, Cipriani P, Di Cola I, Hernández-Rodríguez J, Gómez-Caverzaschi V, Dagna L, Tomelleri A, Makowska J, Brzezinska O, Iagnocco A, Bellis E, Caggiano V, Gaggiano C, Tarsia M, Mormile I, Emmi G, Sfriso P, Monti S, Erten Ş, Del Giudice E, Lubrano R, Conti G, Olivieri AN, Lo Gullo A, Tharwat S, Karamanakos A, Gidaro A, Maggio MC, La Torre F, Cardinale F, Ogunjimi B, Maier A, Sebastiani GD, Opris-Belinski D, Frassi M, Viapiana O, Bizzi E, Carubbi F, Fotis L, Tufan A, Kardas RC, Więsik-Szewczyk E, Jahnz-Różyk K, Fabiani C, Frediani B, Balistreri A, Rigante D (ORCID:0000-0001-7032-7779), Cantarini L, 362., Ruscitti P, Sota, J, Vitale, A, Lopalco, G, Iannone, F, Morrone, M, Giardini, Ham, D'Agostin, Ma, Antonelli, Ipb, Almaghlouth, I, Asfina, Kn, Khalil, N, Sfikakis, Pp, Laskari, K, Tektonidou, M, Ciccia, F, Iacono, D, Riccio, F, Ragab, G, Hussein, Ma, Govoni, M, Ruffilli, F, Direskeneli, H, Alibaz-Oner, F, Giacomelli, R, Navarini, L, Bartoloni, E, Riccucci, I, Martín-Nares, E, Torres-Ruiz, J, Cipriani, P, Di Cola, I, Hernández-Rodríguez, J, Gómez-Caverzaschi, V, Dagna, L, Tomelleri, A, Makowska, J, Brzezinska, O, Iagnocco, A, Bellis, E, Caggiano, V, Gaggiano, C, Tarsia, M, Mormile, I, Emmi, G, Sfriso, P, Monti, S, Erten, Ş, Del Giudice, E, Lubrano, R, Conti, G, Olivieri, An, Lo Gullo, A, Tharwat, S, Karamanakos, A, Gidaro, A, Maggio, Mc, La Torre, F, Cardinale, F, Ogunjimi, B, Maier, A, Sebastiani, Gd, Opris-Belinski, D, Frassi, M, Viapiana, O, Bizzi, E, Carubbi, F, Fotis, L, Tufan, A, Kardas, Rc, Więsik-Szewczyk, E, Jahnz-Różyk, K, Fabiani, C, Frediani, B, Balistreri, A, Rigante, Donato, Cantarini, L, 362. Ruscitti P, Sota J, Vitale A, Lopalco G, Iannone F, Morrone M, Giardini HAM, D'Agostin MA, Antonelli IPB, Almaghlouth I, Asfina KN, Khalil N, Sfikakis PP, Laskari K, Tektonidou M, Ciccia F, Iacono D, Riccio F, Ragab G, Hussein MA, Govoni M, Ruffilli F, Direskeneli H, Alibaz-Oner F, Giacomelli R, Navarini L, Bartoloni E, Riccucci I, Martín-Nares E, Torres-Ruiz J, Cipriani P, Di Cola I, Hernández-Rodríguez J, Gómez-Caverzaschi V, Dagna L, Tomelleri A, Makowska J, Brzezinska O, Iagnocco A, Bellis E, Caggiano V, Gaggiano C, Tarsia M, Mormile I, Emmi G, Sfriso P, Monti S, Erten Ş, Del Giudice E, Lubrano R, Conti G, Olivieri AN, Lo Gullo A, Tharwat S, Karamanakos A, Gidaro A, Maggio MC, La Torre F, Cardinale F, Ogunjimi B, Maier A, Sebastiani GD, Opris-Belinski D, Frassi M, Viapiana O, Bizzi E, Carubbi F, Fotis L, Tufan A, Kardas RC, Więsik-Szewczyk E, Jahnz-Różyk K, Fabiani C, Frediani B, Balistreri A, Rigante D (ORCID:0000-0001-7032-7779), and Cantarini L

Abstract

Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.

Published
2023

9. Search for anomalies in the neutrino sector with muon spectrometers and large LArTPC imaging detectors at CERN

Author

Antonello, M., Bagliani, D., Baibussinov, B., Bilokon, H., Boffelli, F., Bonesini, M., Calligarich, E., Canci, N., Centro, S., Cesana, A., Cieslik, K., Cline, D. B., Cocco, A. G., Dequal, D., Dermenev, A., Dolfini, R., De Gerone, M., Dussoni, S., Farnese, C., Fava, A., Ferrari, A., Fiorillo, G., Garvey, G. T., Gatti, F., Gibin, D., Gninenko, S., Guber, F., Guglielmi, A., Haranczyk, M., Holeczek, J., Ivashkin, A., Kirsanov, M., Kisiel, J., Kochanek, I., Kurepin, A., Lagoda, J., Lucchini, G., Louis, W. C., Mania, S., Mannocchi, G., Marchini, S., Matveev, V., Menegolli, A., Meng, G., Mills, G. B., Montanari, C., Nicoletto, M., Otwinowski, S., Palczewki, T. J., Passardi, G., Perfetto, F., Picchi, P., Pietropaolo, F., Plonski, P., Rappoldi, A., Raselli, G. L., Rossella, M., Rubbia, C., Sala, P., Scaramelli, A., Segreto, E., Stefan, D., Stepaniak, J., Sulej, R., Suvorova, O., Terrani, M., Tlisov, D., Van de Water, R. G., Trinchero, G., Turcato, M., Varanini, F., Ventura, S., Vignoli, C., Wang, H. G., Yang, X., Zani, A., Zaremba, K, Benettoni, M., Bernardini, P., Bertolin, A., Brugnera, R., Calabrese, M., Cecchetti, A., Cecchini, S., Collazuol, G., Creti, P., Corso, F. Dal, Del Prete, A., De Mitri, I., De Robertis, G., De Serio, M., Esposti, L. Degli, Di Ferdinando, D., Dore, U., Dusini, S., Fabbricatore, P., Fanin, C., Fini, R. A., Fiore, G., Garfagnini, A., Giacomelli, G., Giacomelli, R., Guandalini, C., Guerzoni, M., Kose, U., Laurenti, G., Laveder, M., Lippi, I., Loddo, F., Longhin, A., Loverre, P., Mancarella, G., Mandrioli, G., Margiotta, A., Marsella, G., Mauri, N., Medinaceli, E., Mengucci, A., Mezzetto, M., Michinelli, R., Muciaccia, M. T., Orecchini, D., Paoloni, A., Papadia, G., Pastore, A., Patrizii, L., Pozzato, M., Rosa, G., Sahnounm, Z., Simone, S., Sioli, M., Sirri, G., Spurio, M., Stanco, L., Surdo, A., Tenti, M., Togo, V., Ventura, M., and Zago, M.

Subjects
Physics - Instrumentation and Detectors, High Energy Physics - Experiment, High Energy Physics - Phenomenology
Abstract

A new experiment with an intense ~2 GeV neutrino beam at CERN SPS is proposed in order to definitely clarify the possible existence of additional neutrino states, as pointed out by neutrino calibration source experiments, reactor and accelerator experiments and measure the corresponding oscillation parameters. The experiment is based on two identical LAr-TPCs complemented by magnetized spectrometers detecting electron and muon neutrino events at Far and Near positions, 1600 m and 300 m from the proton target, respectively. The ICARUS T600 detector, the largest LAr-TPC ever built with a size of about 600 ton of imaging mass, now running in the LNGS underground laboratory, will be moved at the CERN Far position. An additional 1/4 of the T600 detector (T150) will be constructed and located in the Near position. Two large area spectrometers will be placed downstream of the two LAr-TPC detectors to perform charge identification and muon momentum measurements from sub-GeV to several GeV energy range, greatly complementing the physics capabilities. This experiment will offer remarkable discovery potentialities, collecting a very large number of unbiased events both in the neutrino and antineutrino channels, largely adequate to definitely settle the origin of the observed neutrino-related anomalies., Comment: Contribution to the European Strategy for Particle Physics - Open Symposium Preparatory Group, Kracow 10-12 September 2012

Published
2012

10. Search for 'anomalies' from neutrino and anti-neutrino oscillations at Delta_m^2 ~ 1eV^2 with muon spectrometers and large LAr-TPC imaging detectors

Author

Antonello, M., Bagliani, D., Baibussinov, B., Bilokon, H., Boffelli, F., Bonesini, M., Calligarich, E., Canci, N., Centro, S., Cesana, A., Cieslik, K., Cline, D. B., Cocco, A. G., Dequal, D., Dermenev, A., Dolfini, R., De Gerone, M., Dussoni, S., Farnese, C., Fava, A., Ferrari, A., Fiorillo, G., Garvey, G. T., Gatti, F., Gibin, D., Gninenko, S., Guber, F., Guglielmi, A., Haranczyk, M., Holeczek, J., Ivashkin, A., Kirsanov, M., Kisiel, J., Kochanek, I., Kurepin, A., Łagoda, J., Lucchini, G., Louis, W. C., Mania, S., Mannocchi, G., Marchini, S., Matveev, V., Menegolli, A., Meng, G., Mills, G. B., Montanari, C., Nicoletto, M., Otwinowski, S., Palczewski, T. J., Passardi, G., Perfetto, F., Picchi, P., Pietropaolo, F., Płoński, P., Rappoldi, A., Raselli, G. L., Rossella, M., Rubbia, C., Sala, P., Scaramelli, A., Segreto, E., Stefan, D., Stepaniak, J., Sulej, R., Suvorova, O., Terrani, M., Tlisov, D., Van de Water, R. G., Trinchero, G., Turcato, M., Varanini, F., Ventura, S., Vignoli, C., Wang, H. G., Yang, X., Zani, A., Zaremba, K., Benettoni, M., Bernardini, P., Bertolin, A., Bozza, C., Brugnera, R., Cecchetti, A., Cecchini, S., Collazuol, G., Creti, P., Corso, F. Dal, De Mitri, I., De Robertis, G., De Serio, M., Esposti, L. Degli, Di Ferdinando, D., Dore, U., Dusini, S., Fabbricatore, P., Fanin, C., Fini, R. A., Fiore, G., Garfagnini, A., Giacomelli, G., Giacomelli, R., Grelli, G., Guandalini, C., Guerzoni, M., Kose, U., Laurenti, G., Laveder, M., Lippi, I., Loddo, F., Longhin, A., Loverre, P., Mancarella, G., Mandrioli, G., Margiotta, A., Marsella, G., Mauri, N., Medinaceli, E., Mengucci, A., Mezzetto, M., Michinelli, R., Muciaccia, M. T., Orecchini, D., Paoloni, A., Pastore, A., Patrizii, L., Pozzato, M., Rescigno, R., Rosa, G., Simone, S., Sioli, M., Sirri, G., Spurio, M., Stanco, L., Stellacci, S., Surdo, A., Tenti, M., Togo, V., Ventura, M., and Zago, M.

Subjects
Physics - Instrumentation and Detectors, High Energy Physics - Experiment
Abstract

This proposal describes an experimental search for sterile neutrinos beyond the Standard Model with a new CERN-SPS neutrino beam. The experiment is based on two identical LAr-TPC's followed by magnetized spectrometers, observing the electron and muon neutrino events at 1600 and 300 m from the proton target. This project will exploit the ICARUS T600, moved from LNGS to the CERN "Far" position. An additional 1/4 of the T600 detector will be constructed and located in the "Near" position. Two spectrometers will be placed downstream of the two LAr-TPC detectors to greatly complement the physics capabilities. Spectrometers will exploit a classical dipole magnetic field with iron slabs, and a new concept air-magnet, to perform charge identification and muon momentum measurements in a wide energy range over a large transverse area. In the two positions, the radial and energy spectra of the nu_e beam are practically identical. Comparing the two detectors, in absence of oscillations, all cross sections and experimental biases cancel out, and the two experimentally observed event distributions must be identical. Any difference of the event distributions at the locations of the two detectors might be attributed to the possible existence of {\nu}-oscillations, presumably due to additional neutrinos with a mixing angle sin^2(2theta_new) and a larger mass difference Delta_m^2_new. The superior quality of the LAr imaging TPC, in particular its unique electron-pi_zero discrimination allows full rejection of backgrounds and offers a lossless nu_e detection capability. The determination of the muon charge with the spectrometers allows the full separation of nu_mu from anti-nu_mu and therefore controlling systematics from muon mis-identification largely at high momenta., Comment: Experiment proposal

Published
2012

11. New Lower Limits on the Lifetime of Heavy Neutrino Radiative Decay

Author

Cecchini, S., Centomo, D., Giacomelli, G., Giacomelli, R., Giorgini, M., Patrizii, L., Popa, V., and Serbanuut, C. G.

Subjects
High Energy Physics - Experiment
Abstract

The data collected during the 2006 total solar eclipse are analyzed in the search for signals produced by a hypothetical radiative decay of massive neutrinos. In the absence of the expected light pattern, we set lower limits for the massive neutrino components proper lifetime. The reached sensitivity indicates thet these are the best limits obtainable with this method., Comment: 15 pages, 9 figures

Published
2009
Full Text
View/download PDF

12. Results of the Search for Strange Quark Matter and Q-balls with the SLIM Experiment

Author

Cecchini, S., Cozzi, M., Di Ferdinando, D., Errico, M., Fabbri, F., Giacomelli, G., Giacomelli, R., Giorgini, M., Kumar, A., McDonald, J., Mandrioli, G., Manzoor, S., Margiotta, A., Medinaceli, E., Patrizii, L., Pinfold, J., Popa, V., Qureshi, I. E., Saavedra, O., Sahnoun, Z., Sirri, G., Spurio, M., Togo, V., Valieri, C., Velarde, A., and Zanini, A.

Subjects
High Energy Physics - Experiment
Abstract

The SLIM experiment at the Chacaltaya high altitude laboratory was sensitive to nuclearites and Q-balls, which could be present in the cosmic radiation as possible Dark Matter components. It was sensitive also to strangelets, i.e. small lumps of Strange Quark Matter predicted at such altitudes by various phenomenological models. The analysis of 427 m^2 of Nuclear Track Detectors exposed for 4.22 years showed no candidate event. New upper limits on the flux of downgoing nuclearites and Q-balls at the 90% C.L. were established. The null result also restricts models for strangelets propagation through the Earth atmosphere., Comment: 14 pages, 11 EPS figures

Published
2008
Full Text
View/download PDF

13. Magnetic Monopole Search at high altitude with the SLIM experiment

Author

Balestra, S., Cecchini, S., Cozzi, M., Errico, M., Fabbri, F., Giacomelli, G., Giacomelli, R., Giorgini, M., Kumar, A., Manzoor, S., McDonald, J., Mandrioli, G., Marcellini, S., Margiotta, A., Medinaceli, E., Patrizii, L., Pinfold, J., Popa, V., Qureshi, I. E., Saavedra, O., Sahnoun, Z., Sirri, G., Spurio, M., Togo, V., Velarde, A., and Zanini, A.

Subjects
High Energy Physics - Experiment
Abstract

The SLIM experiment was a large array of nuclear track detectors located at the Chacaltaya high altitude Laboratory (5230 m a.s.l.). The detector was in particular sensitive to Intermediate Mass Magnetic Monopoles, with masses 10^5 < M <10^{12} GeV. From the analysis of the full detector exposed for more than 4 years a flux upper limit of 1.3 x 10^{-15} cm^{-2} s^{-1} sr^{-1} for downgoing fast Intermediate Mass Monopoles was established at the 90% C.L., Comment: 11 pages. 11 EPS figures. Added Fig. 5 and ref. [15]. Added more details in Sect. 2 and 3

Published
2008
Full Text
View/download PDF

14. Bulk Etch Rate Measurements and Calibrations of Plastic Nuclear Track Detectors

Author

Balestra, S., Cozzi, M., Giacomelli, G., Giacomelli, R., Giorgini, M., Kumar, A., Mandrioli, G., Manzoor, S., Margiotta, A. R., Medinaceli, E., Patrizii, L., Popa, V., Qureshi, I. E., Rana, M. A., Sirri, G., Spurio, M., Togo, V., and Valieri, C.

Subjects
Physics - Instrumentation and Detectors
Abstract

New calibrations of CR39 and Makrofol nuclear track detectors have been obtained using 158 A GeV Pb (82+) and In (49+) ions; a new method for the bulk etch rate determination, using both cone height and base diameter measurements was developed. The CR39 charge resolution based on the etch-pit base area measurement is adequate to identify nuclear fragments in the interval 7 <= Z/beta <= 49. For CR39 the detection threshold is at REL~50 MeV cm^2/g, corresponding to a nuclear fragment with Z/beta~7. Base cone area distributions for Makrofol foils exposed to Pb (82+) ions have shown for the first time all peaks due to nuclear fragments with Z > 50; the distribution of the etched cone heights shows well separated individual peaks for Z/beta = 78 - 83 (charge pickup). The Makrofol detection threshold is at REL 2700 MeV cm^2/g, corresponding to a nuclear fragment with Z/beta~50., Comment: 11 pages, 5 EPS figures. Submitted to Nucl. Instr. Meth. B

Published
2006
Full Text
View/download PDF

15. Search for possible solar neutrino radiative decays during total solar eclipses

Author

Cecchini, S., Centomo, D., Giacomelli, G., Giacomelli, R., and Popa, V.

Subjects
High Energy Physics - Experiment
Abstract

Total solar eclipses (TSEs) offer a good opportunity to look for photons produced in possible radiative decays of solar neutrinos. In this paper we briefly review the physics bases of such searches as well as the existing limits on the neutrino proper lifetimes obtained by such experiments. We the report on the observations performed in occasion of the 29 March 2006 TSE, from Waw an Namos, Libya., Comment: Presented at the SPSE2006, Waw an Namos, Libya, 27-29 March 2006

Published
2006

16. Rare Particle Searches with the high altitude SLIM experiment

Author

Balestra, S., Cecchini, S., Fabbri, F., Giacomelli, G., Giacomelli, R., Giorgini, M., Kumar, A., Manzoor, S., McDonald, J., Margiotta, A., Medinaceli, E., Nogales, J., Patrizii, L., Popa, V., Quereshi, I., Saavedra, O., Sher, G., Shahzad, M., Spurio, M., Ticona, R., Togo, V., Velarde, A., and Zanini, A.

Subjects
High Energy Physics - Experiment
Abstract

The search for rare particles in the cosmic radiation remains one of the main aims of non-accelerator particle astrophysics. Experiments at high altitude allow lower mass thresholds with respect to detectors at sea level or underground. The SLIM experiment is a large array of nuclear track detectors located at the Chacaltaya High Altitude Laboratory (5290 m a.s.l.). The preliminary results from the analysis of a part of the first 236 sq.m exposed for more than 3.6 y are here reported. The detector is sensitive to Intermediate Mass Magnetic Monopoles and to SQM nuggets and Q-balls, which are possible Dark Matter candidates., Comment: Paper presented by G. Giacomelli at the European Conference on High Energy Physics, July 21-27 2005, Lisboa, Portugal

Published
2006

17. Search for nuclearites with the SLIM detector

Author

Balestra, S., Cecchini, S., Giacomelli, G., Giacomelli, R., Giorgini, M., Manzoor, S., Patrizii, L., Popa, V., and Saavedra, O.

Subjects
High Energy Physics - Experiment
Abstract

The strange quark matter (SQM) may be the ground state of QCD; nuggets of SQM could be present in cosmic rays (CR). SLIM is a large area experiment, using CR39 and Makrofol track etch detectors, presently deployed at the high altitude CR Laboratory of Chacaltaya, Bolivia. We discuss the expected properties of SQM, from the point of view of its search with SLIM. We present also some preliminary results from SLIM., Comment: Presented at the C2CR Conference, Prague, 2005

Published
2006

18. Science,technology and society

Author

Giacomelli, G. and Giacomelli, R.

Subjects
Physics - Physics and Society
Abstract

We shall discuss some aspects of science and technology, their increasing role in the society, the fast advances in modern science, the apparent decrease of interest of the young generation in basic sciences, the importance of proper science popularization for better public education and awareness in scientific fields., Comment: Lecture at the 7th School on Non-Accelerator Astroparticle Physics, Trieste,Italy,2004

Published
2005
Full Text
View/download PDF

19. Search for possible neutrino radiative decays during the 2001 total solar eclipse

Author

Cecchini, S., Centomo, D., Giacomelli, G., Giacomelli, R., Popa, V., Serbanut, C. G., and Serra, R.

Subjects
High Energy Physics - Experiment
Abstract

We present the results of the observations performed in the occasion of the June 21, 2001 total solar eclipse, looking for visible photons emitted trough a possible radiative decay of solar neutrinos. We establish lower limits for the neutrino proper lifetimes larger than 1000 s/eV, for neutrino masses larger than 0.01 eV., Comment: 18 pages, 11 figures, accepted by Astopart. Phys, updated references

Published
2004
Full Text
View/download PDF

21. Limits on radiative decays of solar neutrinos from a measurement during a solar eclipse

Author

Cecchini, S., Giacomelli, G., Giacomelli, R., Hasegan, D., Maris, O., Popa, V., Serra, R., Serrazanetti, M., Stefanov, L., Tasca, L., and Valeanu, V.

Subjects
High Energy Physics - Experiment
Abstract

A search for possible radiative decays of solar neutrinos with emission of photons in the visible range was performed during the total solar eclipse of August 11, 1999. Due to very bad weather conditions our two telescopes were unable to collect useful data; fortunately we obtained several video camera images from a local TV station. An analysis of the digitised images is presented and limits on the lifetime for radiative decay are discussed., Comment: 10 pages, 1 tablee, 4 PS figures included with epsfig

Published
2000
Full Text
View/download PDF

22. Hadron-hadron and hadron-nuclei collisions at high energies

Author

Giacomelli, G. and Giacomelli, R.

Subjects
High Energy Physics - Experiment
Abstract

A brief review is made of the present situation of hadron-hadron and hadron-nuclei total elastic and inelastic cross sections at high energies, Comment: 7 pages

Published
2000

23. Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases

Author

Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, and Mecchia M

Subjects
preferences, biologic drugs, rheumatic disease, decision-making, Medicine (General), R5-920
Abstract

Luciana Scalone,1 Piercarlo Sarzi-Puttini,2 Luigi Sinigaglia,3 Carlomaurizio Montecucco,4 Roberto Giacomelli,5 Giovanni Lapadula,6 Ignazio Olivieri,7,8,† Angela Maria Giardino,9 Paolo Angelo Cortesi,1 Lorenzo Giovanni Mantovani,1 Monica Mecchia9On behalf of the CARA Study Group1Centre of Research on Public Health, University of Milano-Bicocca, and CHARTA Foundation, Milan, Italy; 2Rheumatology Unit, L. Sacco University Hospital, 3Rheumatology Unit, G. Pini Hospital, Milan, Italy; 4University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; 5Rheumatology Unit School of Medicine, University of L’Aquila, L’Aquila, Italy; 6Rheumatology Unit, University of Bari, Bari, Italy; 7Rheumatology Department of Lucania, San Carlo Hospital of Potenza, Potenza, Italy; 8Madonna delle Grazie Hospital of Matera, Matera, Italy; 9MSD Italy, Rome, Italy†Dr Ignazio Olivieri passed away on July 28, 2017Objective: To estimate preferences in relevant treatment characteristics evaluated by different groups involved in the management of patients with rheumatic diseases.Subjects and methods: We surveyed patients with rheumatic diseases, and rheumatologists, nurses, and pharmacists with experience in treatment with/provision of biologic drugs for these patients. Through a discrete choice experiment, participants evaluated 16 possible scenarios in which pairs of similarly efficacious treatments were described with six characteristics: 1) frequency of administration; 2) mode and place of administration; 3) manner, helpfulness, efficiency, and courtesy of health personnel; 4) frequency of reactions at the site of drug administration; 5) severity of generalized undesired/allergic reactions; and 6) additional cost. The direction and strength of preferences toward each characteristic level and the relative importance of each characteristic were estimated through a random-effects conditional logistic regression model.Results: In total, 513 patients, 110 rheumatologists, 51 nurses, and 46 pharmacists from 30 centers in Italy participated. Characteristics 3, 4, and 6 were the most important for every subgroup; 1 was least important for patients and rheumatologists, 2 was least important for pharmacists, and 2 and 5 were least important for nurses. For characteristic 2, pharmacists preferred subcutaneous self-injection with a syringe; nurses preferred assisted infusion at an infusion center close to the patient’s home; patients and rheumatologists preferred subcutaneous self-injection with a pen.Conclusion: The different preferences for some characteristics shown by the different groups can play an important role, together with purely clinical aspects, in the choice and consequent benefit of treatments, contributing also to a more satisfactory use of resources.Keywords: preferences, biologic drugs, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, decision making

Published
2018

24. POS0237 ADULT-ONSET STILL’S DISEASE AND COVID 19 SHARE GENETIC EXPRESSION RELATED TO HYPERINFLAMMATION: DEFINING THE POSSIBLE ROLE OF THE SPECIALIZED PRO-RESOLVING LIPID MEDIATOR PROTECTIN D1 IN MODULATING MACROPHAGES POLARIZATION AND FUNCTION

Author

Navarini, L., primary, Vomero, M., additional, Currado, D., additional, Berardicurti, O., additional, Biaggi, A., additional, Marino, A., additional, Bearzi, P., additional, Corberi, E., additional, Rigon, A., additional, Arcarese, L., additional, Leuti, A., additional, Fava, M., additional, Fogolari, M., additional, Mattei, A., additional, Ruscitti, P., additional, DI Cola, I., additional, Sambuco, F., additional, Travaglino, F., additional, Angeletti, S., additional, Ursini, F., additional, Mariani, E., additional, Agrò, F. E., additional, Cipriani, P., additional, Iagnocco, A., additional, Antonelli Incalzi, R., additional, Maccarrone, M., additional, and Giacomelli, R., additional

Published
2023
Full Text
View/download PDF

26. POS0541 INFLAMMATORY RHEUMATIC DISEASES (IRD) WITH ONSET AFTER SARS-COV-2 INFECTION OR COVID-19 VACCINATION: A COHORT STUDY FROM THE COVID-19 & ASD COLLABORATIVE STUDY GROUP

Author

Ursini, F., primary, Ruscitti, P., additional, Addimanda, O., additional, Foti, R., additional, Raimondo, V., additional, Murdaca, G., additional, Caira, V., additional, Pigatto, E., additional, Cuomo, G., additional, Lo Gullo, A., additional, Cavazzana, I., additional, Campochiaro, C., additional, Naclerio, C., additional, De Angelis, R., additional, Ciaffi, J., additional, Mancarella, L., additional, Brusi, V., additional, Marchetti, E., additional, Motta, F., additional, Visentini, M., additional, Lorusso, S., additional, De Santis, M., additional, De Luca, G., additional, Massaro, L., additional, Olivo, D., additional, Pellegrini, R., additional, Luppino, J. M. E., additional, DI Cola, I., additional, Varcasia, G., additional, Caso, F., additional, Reta, M., additional, Dagna, L., additional, Selmi, C., additional, Iagnocco, A., additional, Giacomelli, R., additional, Iannone, F., additional, and Ferri, C., additional

Published
2023
Full Text
View/download PDF

27. AB0431 CANAKINUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN STILL’S DISEASE AND DIFFERENCES BETWEEN THE SYSTEMIC AND THE CHRONIC-ARTICULAR COURSES: REAL-LIFE EXPERIENCE FROM THE INTERNATIONAL AIDA REGISTRY

Author

Vitale, A., primary, Caggiano, V., additional, Maggio, M. C., additional, Lopalco, G., additional, Emmi, G., additional, Sota, J., additional, La Torre, F., additional, Ruscitti, P., additional, Bartoloni, E., additional, Conti, G., additional, Fabiani, C., additional, Mattioli, I., additional, Gaggiano, C., additional, Cardinale, F., additional, Dagna, L., additional, Campochiaro, C., additional, Giacomelli, R., additional, Balistreri, A., additional, Laskari, K., additional, Tufan, A., additional, Ragab, G., additional, Almaghlouth, I., additional, Więsik-Szewczyk, E., additional, Pereira, R. M., additional, Frediani, B., additional, Iannone, F., additional, Sfikakis, P., additional, and Cantarini, L., additional

Published
2023
Full Text
View/download PDF

29. Exposure to air pollution as an environmental determinant of how Sjögren's disease is expressed at diagnosis

Author

Brito-Zeron, P., Flores-Chavez, A., Ng, W. -F, Horvath, I. Fanny, Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Ozkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Abacar, K., Bartoloni, E., Rischmueller, M., Reis-de Oliveira, F., Trevisani, V. Fernandes Moca, Jurcut, C., Fugmann, Cecilia, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Szanto, A., Farris, A. D., Villa, M., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Inanc, N., Ramos-Casals, M., Brito-Zeron, P., Flores-Chavez, A., Ng, W. -F, Horvath, I. Fanny, Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Ozkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Abacar, K., Bartoloni, E., Rischmueller, M., Reis-de Oliveira, F., Trevisani, V. Fernandes Moca, Jurcut, C., Fugmann, Cecilia, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Szanto, A., Farris, A. D., Villa, M., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Inanc, N., and Ramos-Casals, M.

Abstract

ObjectiveTo analyse how the potential exposure to air pollutants can influence the key components at the time of diagnosis of Sjogren's phenotype (epidemiological profile, sicca symptoms, and systemic disease). MethodsFor the present study, the following variables were selected for harmonisation and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Air pollution indexes per country were defined according to the OECD (1990-2021), including emission data of nitrogen and sulphur oxides (NO/SO), particulate matter (PM2.5 and 1.0), carbon monoxide (CO) and volatile organic compounds (VOC) calculated per unit of GDP, Kg per 1000 USD.ResultsThe results of the chi-square tests of independence for each air pollutant with the frequency of dry eyes at diagnosis showed that, except for one, all variables exhibited p-values <0.0001. The most pronounced disparities emerged in the dry eye prevalence among individuals inhabiting countries with the highest NO/SO exposure, a surge of 4.61 percentage points compared to other countries, followed by CO (3.59 points), non-methane (3.32 points), PM2.5 (3.30 points), and PM1.0 (1.60 points) exposures. Concerning dry mouth, individuals residing in countries with worse NO/SO exposures exhibited a heightened frequency of dry mouth by 2.05 percentage points (p<0.0001), followed by non-methane exposure (1.21 percentage points increase, p=0.007). Individuals inhabiting countries with the worst NO/SO, CO, and PM2.5 pollution levels had a higher mean global ESSDAI score than those in lower-risk nations (all p-values <0.0001). When systemic disease was stratified according to DAS into low, moderate, and high systemic activity levels, a heightened proportion of individuals manifesting moderate/severe systemic activity was observed in countries with worse exposures to NO/SO, CO, and PM2.5 pollutant levels. ConclusionFor the first time, we suggest that pollution levels could

Published
2023
Full Text
View/download PDF

30. Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjögren's syndrome

Author

Flores-Chavez, A., Brito-Zeron, P., Ng, W. -f., Szanto, A., Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Oezkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Inanc, N., Bartoloni, E., Rischmueller, M., Oliveira, F. Reis-de, Trevisani, V. Fernandes Moca, Jurcut, C., Nordmark, Gunnel, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Horvath, I. Fanny, Farris, A. D., Simoncelli, E., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Abacar, K., Ramos-Casals, M., Flores-Chavez, A., Brito-Zeron, P., Ng, W. -f., Szanto, A., Rasmussen, A., Priori, R., Baldini, C., Armagan, B., Oezkiziltas, B., Praprotnik, S., Suzuki, Y., Quartuccio, L., Hernandez-Molina, G., Inanc, N., Bartoloni, E., Rischmueller, M., Oliveira, F. Reis-de, Trevisani, V. Fernandes Moca, Jurcut, C., Nordmark, Gunnel, Carubbi, F., Hofauer, B., Valim, V., Pasoto, S. G., Retamozo, S., Atzeni, F., Fonseca-Aizpuru, E., Lopez-Dupla, M., Giacomelli, R., Nakamura, H., Akasbi, M., Thompson, K., Horvath, I. Fanny, Farris, A. D., Simoncelli, E., Bombardieri, S., Kilic, L., Tufan, A., Pirkmajer, K. Perdan, Fujisawa, Y., De Vita, S., Abacar, K., and Ramos-Casals, M.

Abstract

Objective To analyse how the key components at the time of diagnosis of the Sjogren's phenotype (epidemiological profile, sicca symptoms, and systemic disease) can be influenced by the potential exposure to climate-related natural hazards. Methods For the present study, the following variables were selected for harmonisation and refinement: age, sex, country, fulfilment of 2002/2016 criteria items, dry eyes, dry mouth, and overall ESSDAI score. Climate-related hazards per country were defined according to the OECD and included seven climate-related hazard types: extreme temperature, extreme precipitation, drought, wildfire, wind threats, river flooding, and coastal flooding. Climatic variables were defined as dichotomous variables according to whether each country is ranked among the ten countries with the most significant exposure. Results After applying data-cleaning techniques and excluding people from countries not included in the OECD climate rankings, the database study analysed 16,042 patients from 23 countries. The disease was diagnosed between 1 and 3 years earlier in people living in countries included among the top 10 worst exposed to extreme precipitation, wildfire, wind threats, river flooding, and coastal flooding. A lower frequency of dry eyes was observed in people living in countries exposed to wind threats, river flooding, and coastal flooding, with a level of statistical association being classified as strong (p<0.0001 for the three variables). The frequency of dry mouth was significantly lower in people living in countries exposed to river flooding (p<0.0001) and coastal flooding (p<0.0001). People living in countries included in the worse climate scenarios for extreme temperature (p<0.0001) and river flooding (p<0.0001) showed a higher mean ESSDAI score in comparison with people living in no-risk countries. In contrast, those living in countries exposed to worse climate scenarios for wind threats (p<0.0001) and coastal flooding

Published
2023
Full Text
View/download PDF

31. A patient-driven registry on Behçet's disease: the AIDA for patients pilot project

Author

Gaggiano, C, Del Bianco, A, Sota, J, Gentileschi, S, Ruscitti, P, Giacomelli, R, Piga, M, Crisafulli, F, Monti, S, Emmi, G, De Paulis, A, Vitale, A, Tarsia, M, Caggiano, V, Nuzzolese, R, Parretti, V, Fabiani, C, Lopalco, G, Maier, A, Cattalini, M, Rigante, Donato, Govoni, M, Li Gobbi, F, Guiducci, S, Parronchi, P, Marino, A, Ciccia, F, Maggio, Mc, Aragona, E, Bartoloni, E, Iagnocco, A, Viapiana, O, Sebastiani, Gd, Guerriero, S, Insalaco, A, Del Giudice, E, Conti, G, Barone, P, Olivieri, An, Brucato, A, Carubbi, F, Triggianese, P, Mauro, A, Tosi, Gm, Fonollosa, A, Giardini, Ham, Ragab, G, Tharwat, S, Hernández-Rodríguez, J, Sfikakis, Pp, Laskari, K, Karamanakos, A, Espinosa, G, Shahram, F, Direskeneli, H, Hinojosa-Azaola, A, Opris-Belinski, D, Almaghlouth, Ia, Hatemi, G, Eksin, Ma, Önen, F, Więsik-Szewczyk, E, Akkoç, N, Tufan, A, Şahin, A, Erten, Ş, Ozen, S, Batu, Ed, Frediani, B, Balistreri, A, Cantarini, L, Rigante D (ORCID:0000-0001-7032-7779), Gaggiano, C, Del Bianco, A, Sota, J, Gentileschi, S, Ruscitti, P, Giacomelli, R, Piga, M, Crisafulli, F, Monti, S, Emmi, G, De Paulis, A, Vitale, A, Tarsia, M, Caggiano, V, Nuzzolese, R, Parretti, V, Fabiani, C, Lopalco, G, Maier, A, Cattalini, M, Rigante, Donato, Govoni, M, Li Gobbi, F, Guiducci, S, Parronchi, P, Marino, A, Ciccia, F, Maggio, Mc, Aragona, E, Bartoloni, E, Iagnocco, A, Viapiana, O, Sebastiani, Gd, Guerriero, S, Insalaco, A, Del Giudice, E, Conti, G, Barone, P, Olivieri, An, Brucato, A, Carubbi, F, Triggianese, P, Mauro, A, Tosi, Gm, Fonollosa, A, Giardini, Ham, Ragab, G, Tharwat, S, Hernández-Rodríguez, J, Sfikakis, Pp, Laskari, K, Karamanakos, A, Espinosa, G, Shahram, F, Direskeneli, H, Hinojosa-Azaola, A, Opris-Belinski, D, Almaghlouth, Ia, Hatemi, G, Eksin, Ma, Önen, F, Więsik-Szewczyk, E, Akkoç, N, Tufan, A, Şahin, A, Erten, Ş, Ozen, S, Batu, Ed, Frediani, B, Balistreri, A, Cantarini, L, and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

Introduction: This paper describes the creation and preliminary results of a patient-driven registry for the collection of patient-reported outcomes (PROs) and patient-reported experiences (PREs) in Behçet’s disease (BD). Methods: The project was coordinated by the University of Siena and the Italian patient advocacy organization SIMBA (Associazione Italiana Sindrome e Malattia di Behçet), in the context of the AIDA (AutoInflammatory Diseases Alliance) Network programme. Quality of life, fatigue, socioeconomic impact of the disease and therapeutic adherence were selected as core domains to include in the registry. Results: Respondents were reached via SIMBA communication channels in 167 cases (83.5%) and the AIDA Network affiliated clinical centers in 33 cases (16.5%). The median value of the Behçet’s Disease Quality of Life (BDQoL) score was 14 (IQR 11, range 0–30), indicating a medium quality of life, and the median Global Fatigue Index (GFI) was 38.7 (IQR 10.9, range 1–50), expressing a significant level of fatigue. The mean Beliefs about Medicines Questionnaire (BMQ) necessity-concern differential was 0.9 ± 1.1 (range – 1.8–4), showing that the registry participants prioritized necessity belief over concerns to a limited extent. As for the socioeconomic impact of BD, in 104 out of 187 cases (55.6%), patients had to pay from their own pocket for medical exams required to reach the diagnosis. The low family socioeconomic status (p < 0.001), the presence of any major organ involvement (p < 0.031), the presence of gastro-intestinal (p < 0.001), neurological (p = 0.012) and musculoskeletal (p = 0.022) symptoms, recurrent fever (p = 0.002), and headache (p < 0.001) were associated to a higher number of accesses to the healthcare system. Multiple linear regression showed that the BDQoL score could significantly predict the global socioeconomic impact of BD (F = 14.519, OR 1.162 [CI 0.557–1.766], p < 0.001). Discussion: Preliminary results from the AID

Published
2023

32. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Author

Ferri, C., Raimondo, V., Giuggioli, D., Gragnani, L., Lorini, S., Dagna, L., Bosello, Silvia Laura, Foti, R., Riccieri, V., Guiducci, S., Cuomo, G., Tavoni, A., De Angelis, R., Cacciapaglia, F., Zanatta, E., Cozzi, F., Murdaca, G., Cavazzana, I., Romeo, N., Codullo, V., Pellegrini, R., Varcasia, G., De Santis, M., Selmi, C., Abignano, G., Caminiti, M., L'Andolina, M., Olivo, D., Lubrano, E., Spinella, A., Lumetti, F., De Luca, G., Ruscitti, P., Urraro, T., Visentini, M., Bellando-Randone, S., Visalli, E., Testa, D., Sciascia, G., Masini, F., Pellegrino, G., Saccon, F., Balestri, E., Elia, G., Ferrari, S. M., Tonutti, A., Dall'Ara, F., Pagano Mariano, G., Pettiti, G., Zanframundo, G., Brittelli, R., Aiello, V., Dal Bosco, Y., Di Cola, I., Scorpiniti, D., Fusaro, E., Ferrari, T., Gigliotti, P., Campochiaro, C., Francioso, F., Iandoli, C., Caira, V., Zignego, A. L., D'Angelo, S., Franceschini, F., Matucci-Cerinic, M., Giacomelli, R., Doria, A., Santini, Stefano Angelo, Fallahi, P., Iannone, F., Antonelli, A., Bosello S. L. (ORCID:0000-0002-4837-447X), Santini S. A. (ORCID:0000-0003-1956-5899), Ferri, C., Raimondo, V., Giuggioli, D., Gragnani, L., Lorini, S., Dagna, L., Bosello, Silvia Laura, Foti, R., Riccieri, V., Guiducci, S., Cuomo, G., Tavoni, A., De Angelis, R., Cacciapaglia, F., Zanatta, E., Cozzi, F., Murdaca, G., Cavazzana, I., Romeo, N., Codullo, V., Pellegrini, R., Varcasia, G., De Santis, M., Selmi, C., Abignano, G., Caminiti, M., L'Andolina, M., Olivo, D., Lubrano, E., Spinella, A., Lumetti, F., De Luca, G., Ruscitti, P., Urraro, T., Visentini, M., Bellando-Randone, S., Visalli, E., Testa, D., Sciascia, G., Masini, F., Pellegrino, G., Saccon, F., Balestri, E., Elia, G., Ferrari, S. M., Tonutti, A., Dall'Ara, F., Pagano Mariano, G., Pettiti, G., Zanframundo, G., Brittelli, R., Aiello, V., Dal Bosco, Y., Di Cola, I., Scorpiniti, D., Fusaro, E., Ferrari, T., Gigliotti, P., Campochiaro, C., Francioso, F., Iandoli, C., Caira, V., Zignego, A. L., D'Angelo, S., Franceschini, F., Matucci-Cerinic, M., Giacomelli, R., Doria, A., Santini, Stefano Angelo, Fallahi, P., Iannone, F., Antonelli, A., Bosello S. L. (ORCID:0000-0002-4837-447X), and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

Introduction: The impact of COVID-19 pandemic represents a serious challenge for ‘frail’ patients' populations with inflammatory autoimmune systemic diseases such as systemic sclerosis (SSc). We investigated the prevalence and severity of COVID-19, as well the effects of COVID-19 vaccination campaign in a large series of SSc patients followed for the entire period (first 38 months) of pandemic. Patients and method: This prospective survey study included 1755 unselected SSc patients (186 M, 1,569F; mean age 58.7 ± 13.4SD years, mean disease duration 8.8 ± 7.3SD years) recruited in part by telephone survey at 37 referral centers from February 2020 to April 2023. The following parameters were carefully evaluated: i. demographic, clinical, serological, and therapeutical features; ii. prevalence and severity of COVID-19; and iii. safety, immunogenicity, and efficacy of COVID-19 vaccines. Results: The prevalence of COVID-19 recorded during the whole pandemic was significantly higher compared to Italian general population (47.3 % vs 43.3 %, p < 0.000), as well the COVID-19-related mortality (1.91 % vs 0.72 %, p < 0.001). As regards the putative prognostic factors of worse outcome, COVID-19 positive patients with SSc-related interstitial lung involvement showed significantly higher percentage of COVID-19-related hospitalization compared to those without (5.85 % vs 1.73 %; p < 0.0001), as well as of mortality rate (2.01 % vs 0.4 %; p = 0.002). Over half of patients (56.3 %) received the first two plus one booster dose of vaccine; while a fourth dose was administered to 35.6 %, and only few of them (1.99 %) had five or more doses of vaccine. Of note, an impaired seroconversion was recorded in 25.6 % of individuals after the first 2 doses of vaccine, and in 8.4 % of patients also after the booster dose. Furthermore, the absence of T-cell immunoreactivity was observed in 3/7 patients tested by QuantiFERON® SARSCoV-2 Starter Set (Qiagen). The efficacy of vaccines, evalu

Published
2023

35. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases

Author

Guerrini, G, Franzetti, F, Giacomelli, R, Meroni, L, Riva, A, Scire, C, Scrivo, R, Tavio, M, Agostinone, A, Airo, P, Atzeni, F, Bartalesi, F, Bazzichi, L, Berardicurti, O, Cassola, G, Castagna, A, Castelli, F, Cattelan, A, Citriniti, G, Cristini, F, De Rosa, F, Fracassi, E, Galloway, J, La Paglia, G, Moioli, M, Ripamonti, D, Saracino, A, Tani, C, Tascini, C, Tieghi, T, Tinelli, M, Zabotti, A, Sarzi-Puttini, P, Galli, M, Guerrini G., Franzetti F., Giacomelli R., Meroni L., Riva A., Scire C. A., Scrivo R., Tavio M., Agostinone A., Airo P., Atzeni F., Bartalesi F., Bazzichi L., Berardicurti O., Cassola G., Castagna A., Castelli F., Cattelan A., Citriniti G., Cristini F., De Rosa F., Fracassi E., Galloway J., La Paglia G. M. C., Moioli M. C., Ripamonti D., Saracino A., Tani C., Tascini C., Tieghi T., Tinelli M., Zabotti A., Sarzi-Puttini P., Galli M., Guerrini, G, Franzetti, F, Giacomelli, R, Meroni, L, Riva, A, Scire, C, Scrivo, R, Tavio, M, Agostinone, A, Airo, P, Atzeni, F, Bartalesi, F, Bazzichi, L, Berardicurti, O, Cassola, G, Castagna, A, Castelli, F, Cattelan, A, Citriniti, G, Cristini, F, De Rosa, F, Fracassi, E, Galloway, J, La Paglia, G, Moioli, M, Ripamonti, D, Saracino, A, Tani, C, Tascini, C, Tieghi, T, Tinelli, M, Zabotti, A, Sarzi-Puttini, P, Galli, M, Guerrini G., Franzetti F., Giacomelli R., Meroni L., Riva A., Scire C. A., Scrivo R., Tavio M., Agostinone A., Airo P., Atzeni F., Bartalesi F., Bazzichi L., Berardicurti O., Cassola G., Castagna A., Castelli F., Cattelan A., Citriniti G., Cristini F., De Rosa F., Fracassi E., Galloway J., La Paglia G. M. C., Moioli M. C., Ripamonti D., Saracino A., Tani C., Tascini C., Tieghi T., Tinelli M., Zabotti A., Sarzi-Puttini P., and Galli M.

Abstract

OBJECTIVES: To provide evidence-based recommendations for vaccination against influenza virus and S. pneumoniae in patients with autoimmune rheumatic diseases (ARDs). METHODS: A Consensus Committee including physicians with expertise in rheumatic and infectious diseases was established by two Italian scientific societies, Società Italiana di Reumatologia (SIR) and Società Italiana di Malattie Infettive e Tropicali (SIMIT). The experts were invited to develop evidence-based recommendations concerning vaccinations in ARDs patients, based on their clinical status before and after undergoing immunosuppressive treatments. Key clinical questions were formulated for the systematic literature reviews, based on the clinical pathway. A search was made in Medline (via PubMed) according to the original MeSH strategy from October 2009 and a keyword strategy from January 2016 up to December 2017, updating existing EULAR recommendations. Specific recommendations were separately voted and scored from 0 (no agreement with) to 100 (maximal agreement) and supporting evidence graded. The mean and standard deviation of the scores were calculated to determine the level of agreement among the experts' panel for each recommendation. Total cumulative agreement ≥70 defined consensus for each statement. RESULTS: Nine recommendations, based on 6 key clinical questions addressed by the expert committee, were proposed. The aim of this work is to integrate the 2011 EULAR recommendations on vaccination against influenza and S. pneumoniae in ARDs patients. An implementation plan was proposed to improve the vaccination status of these patients and their safety during immunosuppressive treatments. CONCLUSIONS: Influenza and pneumococcus vaccinations are effective and safe in patients with ARDs. More efforts should be made to translate the accumulated evidence into practice.

Published
2020

36. Childhood-onset of primary Sjögren’s syndrome: phenotypic characterization at diagnosis of 158 children

Author

Ramos-Casals, M., Acar-Denizli, N., Vissink, A., Brito-Zeron, P., Li, X., Carubbi, F., Priori, R., Toplak, N., Baldini, C., Faugier-Fuentes, E., Kruize, A. A., Mandl, T., Tomiita, M., Gandolfo, S., Hashimoto, K., Hernandez-Molina, G., Hofauer, B., Mendieta-Zeron, S., Rasmussen, A., Sandhya, P., Sene, D., Trevisani, V. F. M., Isenberg, D., Sundberg, E., Pasoto, S. G., Sebastian, A., Suzuki, Y., Retamozo, S., Xu, B., Giacomelli, R., Gattamelata, A., Bizjak, M., Bombardieri, S., Loor-Chavez, R. -E., Hinrichs, A., Olsson, P., Bootsma, H., Lieberman, S. M., Kostov, B., Horvath, I. -F., Szanto, A., Seror, R., Mariette, X., Kvarnstrom, M., Wahren-Herlenius, M., Praprotnik, S., Solans, R., Nordmark, G., Hammenfors, D., Brun, J. G., Gheita, T. A., Atzeni, F., Armagan, B., Kilic, L., Kalyoncu, U., Nakamura, T., Takagi, Y., Consani, S., Solorzano, F. O., Translational Immunology Groningen (TRIGR), Personalized Healthcare Technology (PHT), Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, and Universitat Politècnica de Catalunya. ADBD - Anàlisi de Dades Complexes per a les Decisions Empresarials

Subjects
Male, Systemic disease, Anti-nuclear antibody, Epidemiology, Autoimmune diseases, Matemàtiques i estadística::Matemàtica aplicada a les ciències [Àrees temàtiques de la UPC], Disease, Severity of Illness Index, Parotid Gland, Medicine, CLASSIFICATION CRITERIA, Pharmacology (medical), Registries, Age of Onset, biology, 92 Biology and other natural sciences::92B Mathematical biology in general [Classificació AMS], Dry eyes, Phenotype, Sjogren's syndrome, Female, epidemiology, Antibody, medicine.symptom, PAROTITIS, medicine.medical_specialty, Biomatemàtica, Adolescent, 62 Statistics::62D05 Sampling theory, sample surveys [Classificació AMS], Childhood, Paediatrics, Humans, Sjogren's Syndrome, paediatrics, AGE, Rheumatology, Peripheral nerve, Rheumatoid factor, autoimmune diseases, Sampling (Statistics), Primary Sjögren Syndrome, childhood, Biomathematics, Matemàtiques i estadística::Estadística aplicada::Estadística biosanitària [Àrees temàtiques de la UPC], business.industry, CLINICAL-FEATURES, medicine.disease, Dry mouth, Dermatology, stomatognathic diseases, biology.protein, Sjogren’s syndrome, CONSENSUS, business, Mostreig (Estadística), Parotitis
Abstract

Objectives To characterize the phenotypic presentation at diagnosis of childhood-onset primary SS. Methods The Big Data Sjögren Project Consortium is an international, multicentre registry using worldwide data-sharing cooperative merging of pre-existing clinical SS databases from the five continents. For this study, we selected those patients in whom the disease was diagnosed below the age of 19 years according to the fulfilment of the 2002/2016 classification criteria. Results Among the 12 083 patients included in the Sjögren Big Data Registry, 158 (1.3%) patients had a childhood-onset diagnosis (136 girls, mean age of 14.2 years): 126 (80%) reported dry mouth, 111 (70%) dry eyes, 52 (33%) parotid enlargement, 118/122 (97%) positive minor salivary gland biopsy and 60/64 (94%) abnormal salivary US study, 140/155 (90%) positive ANA, 138/156 (89%) anti-Ro/La antibodies and 86/142 (68%) positive RF. The systemic EULAR Sjögren’s syndrome disease activity index (ESSDAI) domains containing the highest frequencies of active patients included the glandular (47%), articular (26%) and lymphadenopathy (25%) domains. Patients with childhood-onset primary SS showed the highest mean ESSDAI score and the highest frequencies of systemic disease in 5 (constitutional, lymphadenopathy, glandular, cutaneous and haematological) of the 12 ESSDAI domains, and the lowest frequencies in 4 (articular, pulmonary, peripheral nerve and CNS) in comparison with patients with adult-onset disease. Conclusions Childhood-onset primary SS involves around 1% of patients with primary SS, with a clinical phenotype dominated by sicca features, parotid enlargement and systemic disease. Age at diagnosis plays a key role in modulating the phenotypic expression of the disease.

Published
2021

39. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases

Author

Ferri, C., Gragnani, L., Raimondo, V., Visentini, M., Giuggioli, D., Lorini, S., Foti, R., Cacciapaglia, F., Caminiti, M., Olivo, D., Cuomo, G., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Cavazzana, I., Ruscitti, P., Vadacca, M., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Bosco, Y. D., Amato, G., Masini, F., Mariano, G. P., Brittelli, R., Aiello, V., Scorpiniti, D., Rechichi, G., Varcasia, G., Monti, M., Elia, G., Franceschini, F., Casato, M., Ursini, F., Giacomelli, R., Fallahi, P., Santini, Stefano Angelo, Iannone, F., Salvarani, C., Zignego, A. L., Antonelli, A., Santini S. A. (ORCID:0000-0003-1956-5899), Ferri, C., Gragnani, L., Raimondo, V., Visentini, M., Giuggioli, D., Lorini, S., Foti, R., Cacciapaglia, F., Caminiti, M., Olivo, D., Cuomo, G., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Cavazzana, I., Ruscitti, P., Vadacca, M., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Bosco, Y. D., Amato, G., Masini, F., Mariano, G. P., Brittelli, R., Aiello, V., Scorpiniti, D., Rechichi, G., Varcasia, G., Monti, M., Elia, G., Franceschini, F., Casato, M., Ursini, F., Giacomelli, R., Fallahi, P., Santini, Stefano Angelo, Iannone, F., Salvarani, C., Zignego, A. L., Antonelli, A., and Santini S. A. (ORCID:0000-0003-1956-5899)

Abstract

Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed at evaluating the seroconversion elicited by COVID-19 vaccine over the entire vaccination cycle including the booster dose. Among 478 unselected ASD patients originally evaluated at the end of the first vaccination cycle (time 1), 344 individuals were re-evaluated after a 6-month period (time 2), and 244 after the booster vaccine dose (time 3). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was assessed by measuring serum IgG-neutralizing antibody (NAb) on samples obtained at the three time points in both patients and 502 age-matched controls. In the 244 ASD group that received booster vaccine and monitored over the entire follow-up, the mean serum NAb levels (time 1, 2, and 3: 696.8 ± 52.68, 370.8 ± 41.92, and 1527 ± 74.16SD BAU/mL, respectively; p < 0.0001) were constantly lower compared to controls (p < 0.0001), but they significantly increased after the booster dose compared to the first two measurements (p < 0.0001). The percentage of patients with absent/suboptimal response to vaccine significantly decreased after the booster dose compared to the first and second evaluations (time 1, 2, and 3: from 28.2% to 46.3%, and to 7.8%, respectively; p < 0.0001). Of note, the percentage of patients with absent/suboptimal response after the booster dose was significantly higher compared to controls (19/244, 7.8% vs 1/502, 0.2%; p < 0.0001). Similarly, treatment with immune-modifiers increased the percentage of patients exhibiting absent/suboptimal response (16/122, 13.1% vs 3/122, 2.46%; p = 0.0031). Overall, the above findings indicate the usefulness of booster vaccine administration in ASD patients. Moreover, the persistence of a significantly higher percentage of individuals without effective seroconversion (7.8%), even after the booster dose, warrants for careful monitoring of NAb levels in a

Published
2022

40. Development and implementation of the AIDA International Registry for patients with Behçet's disease

Author

Vitale, A, Della Casa, F, Ragab, G, Almaghlouth, Ia, Lopalco, G, Pereira, Rm, Guerriero, S, Govoni, M, Sfikakis, Pp, Giacomelli, R, Ciccia, F, Monti, S, Ruscitti, P, Piga, M, Lomater, C, Tufan, A, Opris-Belinski, D, Emmi, G, Hernández-Rodríguez, J, Şahin, A, Sebastiani, Gd, Bartoloni, E, Akkoç, N, Gündüz, Ö, Cattalini, M, Conti, Giorgio, Hatemi, G, Maier, A, Parronchi, P, Del Giudice, E, Erten, S, Insalaco, A, Li Gobbi, F, Maggio, Mc, Shahram, F, Caggiano, V, Hegazy, Mt, Asfina, Kn, Morrone, M, Prado, Ll, Dammacco, R, Ruffilli, F, Arida, A, Navarini, L, Pantano, I, Cavagna, L, Conforti, A, Cauli, A, Marucco, Em, Kucuk, H, Ionescu, R, Mattioli, I, Espinosa, G, Araújo, O, Karkaş, B, Canofari, C, Sota, J, Laymouna, Ah, Bedaiwi, Aa, Colella, S, Giardini, Ham, Albano, V, Lo Monaco, A, Fragoulis, Ge, Kardas, Rc, Berlengiero, V, Hussein, Ma, Ricci, F, La Torre, F, Rigante, Donato, Więsik-Szewczyk, E, Frassi, M, Gentileschi, S, Tosi, Gm, Dagostin, Ma, Mahmoud, Aaa, Tarsia, M, Alessio, G, Cimaz, R, Giani, T, Gaggiano, C, Iannone, F, Cipriani, P, Mourabi, M, Spedicato, V, Barneschi, S, Aragona, E, Balistreri, A, Frediani, B, Fabiani, C, Cantarini, L &amp, Autoinflammatory Diseases Alliance (AIDA), Network, Conti G (ORCID:0000-0002-8566-9365), Rigante D (ORCID:0000-0001-7032-7779), Vitale, A, Della Casa, F, Ragab, G, Almaghlouth, Ia, Lopalco, G, Pereira, Rm, Guerriero, S, Govoni, M, Sfikakis, Pp, Giacomelli, R, Ciccia, F, Monti, S, Ruscitti, P, Piga, M, Lomater, C, Tufan, A, Opris-Belinski, D, Emmi, G, Hernández-Rodríguez, J, Şahin, A, Sebastiani, Gd, Bartoloni, E, Akkoç, N, Gündüz, Ö, Cattalini, M, Conti, Giorgio, Hatemi, G, Maier, A, Parronchi, P, Del Giudice, E, Erten, S, Insalaco, A, Li Gobbi, F, Maggio, Mc, Shahram, F, Caggiano, V, Hegazy, Mt, Asfina, Kn, Morrone, M, Prado, Ll, Dammacco, R, Ruffilli, F, Arida, A, Navarini, L, Pantano, I, Cavagna, L, Conforti, A, Cauli, A, Marucco, Em, Kucuk, H, Ionescu, R, Mattioli, I, Espinosa, G, Araújo, O, Karkaş, B, Canofari, C, Sota, J, Laymouna, Ah, Bedaiwi, Aa, Colella, S, Giardini, Ham, Albano, V, Lo Monaco, A, Fragoulis, Ge, Kardas, Rc, Berlengiero, V, Hussein, Ma, Ricci, F, La Torre, F, Rigante, Donato, Więsik-Szewczyk, E, Frassi, M, Gentileschi, S, Tosi, Gm, Dagostin, Ma, Mahmoud, Aaa, Tarsia, M, Alessio, G, Cimaz, R, Giani, T, Gaggiano, C, Iannone, F, Cipriani, P, Mourabi, M, Spedicato, V, Barneschi, S, Aragona, E, Balistreri, A, Frediani, B, Fabiani, C, Cantarini, L &amp, Autoinflammatory Diseases Alliance (AIDA), Network, Conti G (ORCID:0000-0002-8566-9365), and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

Objective: Purpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behçet’s disease (BD). Methods: The Registry is a clinical physician-driven population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been realised to change over time according to future scientific acquisitions and potentially communicate with other existing and future Registries dedicated to BD. Results: Starting from January 31st to November 23rd, 2021, 99 centres from 20 countries in 4 continents have been involved. Forty-eight of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 265 users (99 Principal Investigators, 162 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 5474 fields organised into 15 instruments, including patient’s demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. Conclusions: The development of the AIDA International Registry for BD patients will facilitate the collection of standardised data leading to real-world evidence, enabling international multicentre collaborative research through data sharing, international consultation, dissemination of knowledge, inclusion of patients and families, and ultimately optimisation of scientific efforts and implementation of standardised care.

Published
2022

41. Development and implementation of the AIDA International Registry for patients with VEXAS syndrome

Author

Vitale, A, Caggiano, V, Della Casa, F, Hernández-Rodríguez, J, Frassi, M, Monti, S, Tufan, A, Telesca, S, Conticini, E, Ragab, G, Lopalco, G, Almaghlouth, I, Pereira, Rmr, Yildirim, D, Cattalini, M, Marino, A, Giani, T, La Torre, F, Ruscitti, P, Aragona, E, Wiesik-Szewczyk, E, Del Giudice, E, Sfikakis, Pp, Govoni, M, Emmi, G, Maggio, Mc, Giacomelli, R, Ciccia, F, Conti, Giorgio, Ait-Idir, D, Lomater, C, Sabato, V, Piga, M, Sahin, A, Opris-Belinski, D, Ionescu, R, Bartoloni, E, Franceschini, F, Parronchi, P, de Paulis, A, Espinosa, G, Maier, A, Sebastiani, Gd, Insalaco, A, Shahram, F, Sfriso, P, Minoia, F, Alessio, M, Makowska, J, Hatemi, G, Akkoç, N, Li Gobbi, F, Gidaro, A, Olivieri, An, Al-Mayouf, Sm, Erten, S, Gentileschi, S, Vasi, I, Tarsia, M, Mahmoud, Aaa, Frediani, B, Fares Alzahrani, M, Laymouna, Ah, Ricci, F, Cardinale, F, Jahnz-Rózyk, K, Tosi, Gm, Crisafulli, F, Balistreri, A, Dagostin, Ma, Ghanema, M, Gaggiano, C, Sota, J, Di Cola, I, Fabiani, C, Giardini, Ham, Renieri, A, Fabbiani, A, Carrer, A, Bocchia, M, Caroni, F, Rigante, Donato, Cantarini, L, Conti G (ORCID:0000-0002-8566-9365), Rigante D (ORCID:0000-0001-7032-7779), Vitale, A, Caggiano, V, Della Casa, F, Hernández-Rodríguez, J, Frassi, M, Monti, S, Tufan, A, Telesca, S, Conticini, E, Ragab, G, Lopalco, G, Almaghlouth, I, Pereira, Rmr, Yildirim, D, Cattalini, M, Marino, A, Giani, T, La Torre, F, Ruscitti, P, Aragona, E, Wiesik-Szewczyk, E, Del Giudice, E, Sfikakis, Pp, Govoni, M, Emmi, G, Maggio, Mc, Giacomelli, R, Ciccia, F, Conti, Giorgio, Ait-Idir, D, Lomater, C, Sabato, V, Piga, M, Sahin, A, Opris-Belinski, D, Ionescu, R, Bartoloni, E, Franceschini, F, Parronchi, P, de Paulis, A, Espinosa, G, Maier, A, Sebastiani, Gd, Insalaco, A, Shahram, F, Sfriso, P, Minoia, F, Alessio, M, Makowska, J, Hatemi, G, Akkoç, N, Li Gobbi, F, Gidaro, A, Olivieri, An, Al-Mayouf, Sm, Erten, S, Gentileschi, S, Vasi, I, Tarsia, M, Mahmoud, Aaa, Frediani, B, Fares Alzahrani, M, Laymouna, Ah, Ricci, F, Cardinale, F, Jahnz-Rózyk, K, Tosi, Gm, Crisafulli, F, Balistreri, A, Dagostin, Ma, Ghanema, M, Gaggiano, C, Sota, J, Di Cola, I, Fabiani, C, Giardini, Ham, Renieri, A, Fabbiani, A, Carrer, A, Bocchia, M, Caroni, F, Rigante, Donato, Cantarini, L, Conti G (ORCID:0000-0002-8566-9365), and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

Objective: The aim of this paper is to present the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome, describing its design, construction, and modalities of dissemination. Methods: The present registry is a clinical, physician-driven, population- and electronic-based instrument designed for the retrospective and prospective collection of real-life data. Data gathering is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain real-world evidence for daily patients’ management; the registry may potentially communicate with other on-line tools dedicated to VEXAS syndrome, enhancing international collaboration and data sharing for research purposes. The registry is handy enough to be easily modified to meet future needs regarding VEXAS syndrome. Results: To date (April 2022), 105 Centers from 23 Countries in 4 continents have been involved; 287 users (106 Principal Investigators, 177 Site Investigators, 2 Lead Investigators, and 2 data managers) may already enter the registry for data collection and sharing. The registry includes 4950 fields organised into 18 instruments designed to fully describe patient’s details about demographics, clinical manifestations, symptoms, histologic details about skin and bone marrow biopsies and aspirate, laboratory features, complications, comorbidities, therapies, and healthcare access. Conclusions: This international Registry for patients with VEXAS syndrome will allow the achievement of a comprehensive knowledge about this new disease in a relatively short time with the final goal to obtain real-world evidence data for daily clinical practice. This project can be found on https://clinicaltrials.gov NCT 05200715

Published
2022

42. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry

Author

Sota, J, Vitale, A, Lopalco, G, Pereira, Rmr, Giordano, Hf, Antonelli, Ipb, Makowska, J, Brzezińska, O, Lewandowska-Polak, A, Ruscitti, P, Cipriani, P, Cola, Id, Govoni, M, Ruffili, F, Sfikakis, Pp, Laskari, K, Ragab, G, Hussein, Ma, Gentileschi, S, Gaggiano, C, La Torre, F, Maier, A, Emmi, G, Marino, A, Ciccia, F, Sfriso, P, Maggio, Mc, Bartoloni, E, Lomater, C, Hegazy, Mt, Tektonidou, M, Dagostin, Ma, Opinc, A, Sebastiani, Gd, Giacomelli, R, Giudice, Ed, Olivieri, An, Tufan, A, Kardas, Rk, Nuzzolese, R, Cardinale, F, Więsik-Szewczyk, E, Veronica, P, Tarsia, M, Iannone, F, Della Casa, F, Fabiani, C, Frediani, B, Balistreri, A, Rigante, Donato, Cantarini, L, Rigante D (ORCID:0000-0001-7032-7779), Sota, J, Vitale, A, Lopalco, G, Pereira, Rmr, Giordano, Hf, Antonelli, Ipb, Makowska, J, Brzezińska, O, Lewandowska-Polak, A, Ruscitti, P, Cipriani, P, Cola, Id, Govoni, M, Ruffili, F, Sfikakis, Pp, Laskari, K, Ragab, G, Hussein, Ma, Gentileschi, S, Gaggiano, C, La Torre, F, Maier, A, Emmi, G, Marino, A, Ciccia, F, Sfriso, P, Maggio, Mc, Bartoloni, E, Lomater, C, Hegazy, Mt, Tektonidou, M, Dagostin, Ma, Opinc, A, Sebastiani, Gd, Giacomelli, R, Giudice, Ed, Olivieri, An, Tufan, A, Kardas, Rk, Nuzzolese, R, Cardinale, F, Więsik-Szewczyk, E, Veronica, P, Tarsia, M, Iannone, F, Della Casa, F, Fabiani, C, Frediani, B, Balistreri, A, Rigante, Donato, Cantarini, L, and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

Background/objectives: Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset Still’s disease (AOSD) mostly derive from small case series. Herein we report a registry-based study investigating TCZ efficacy and safety in a cohort of patients with AOSD evaluated by clinical and serum inflammatory markers as well as drug retention rate analysis. Methods: This is an international multicentre study analyzing data from patients with AOSD regularly enrolled in the AIDA registry. TCZ efficacy was evaluated between baseline and last follow-up assessment in terms of changes in the Pouchot score and laboratory findings. Drug-retention rate was estimated by the Kaplan-Meier method, while Cox-regression analysis was employed to detect potential predictive factors of treatment withdrawal. Results: Data from 31 patients (15 men, 16 women) refractory to the conventional therapies and treated with TCZ were extracted from the AIDA registry. Mean ± SD time of treatment duration with TCZ was 24.32 ± 20.57 months. Pouchot score significantly decreased from baseline 2.00 (4.00) to the last follow-up assessment 00.00 (00.00), p=0.003). Similarly, laboratory parameters significantly decreased from baseline to the last follow-up visit. With regard to drug survival, cumulative TCZ retention rate at 12-, 24-, and 36-month follow-up visit were 83.1%, 71.7% and 63.7%, respectively, without significant differences between biologic naïve patients and those previously treated with other biologics (p=0.329). Likewise, no significant differences were observed between chronic articular course of AOSD and other types of disease course (p=0.938) or between patients co-administered with conventional immunosuppressants and patients receiving TCZ as monotherapy (p=0.778). Cox-regression analysis identified no variable associated with a higher hazard of treatment withdrawal. Treatment was discontinued in 9 patients due to long-term remission (n=4), adverse events (n=2), loss of efficacy (n=1)

Published
2022

43. Development and implementation of the AIDA International Registry for patients with Still’s disease

Author

Vitale, A, Della Casa, F, Lopalco, G, Pereira, Rm, Ruscitti, P, Giacomelli, R, Ragab, G, La Torre, F, Bartoloni, E, Del Giudice, E, Lomater, C, Emmi, G, Govoni, M, Maggio, Mc, Maier, A, Makowska, J, Ogunjimi, B, Sfikakis, Pp, Sfriso, P, Gaggiano, C, Iannone, F, Dagostin, Ma, Di Cola, I, Navarini, L, Ahmed Mahmoud, Aa, Cardinale, F, Riccucci, I, Paroli, Mp, Marucco, Em, Mattioli, I, Sota, J, Abbruzzese, A, Antonelli, Ipb, Cipriani, P, Tufan, A, Fabiani, C, Ramadan, Mm, Cattalini, M, Kardas, Rc, Sebastiani, Gd, Giardini, Ham, Hernández-Rodríguez, J, Mastrorilli, V, Więsik-Szewczyk, E, Frassi, M, Caggiano, V, Telesca, S, Giordano, Hf, Guadalupi, E, Balistreri, A, Rigante, Donato, Cantarini, L., Rigante D (ORCID:0000-0001-7032-7779), Vitale, A, Della Casa, F, Lopalco, G, Pereira, Rm, Ruscitti, P, Giacomelli, R, Ragab, G, La Torre, F, Bartoloni, E, Del Giudice, E, Lomater, C, Emmi, G, Govoni, M, Maggio, Mc, Maier, A, Makowska, J, Ogunjimi, B, Sfikakis, Pp, Sfriso, P, Gaggiano, C, Iannone, F, Dagostin, Ma, Di Cola, I, Navarini, L, Ahmed Mahmoud, Aa, Cardinale, F, Riccucci, I, Paroli, Mp, Marucco, Em, Mattioli, I, Sota, J, Abbruzzese, A, Antonelli, Ipb, Cipriani, P, Tufan, A, Fabiani, C, Ramadan, Mm, Cattalini, M, Kardas, Rc, Sebastiani, Gd, Giardini, Ham, Hernández-Rodríguez, J, Mastrorilli, V, Więsik-Szewczyk, E, Frassi, M, Caggiano, V, Telesca, S, Giordano, Hf, Guadalupi, E, Balistreri, A, Rigante, Donato, Cantarini, L., and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

Objective: Aim of this paper is to present the design, construction, and modalities of dissemination of the AutoInflammatory Disease Alliance (AIDA) International Registry for patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD), which are the pediatric and adult forms of the same autoinflammatory disorder. Methods: This Registry is a clinical, physician-driven, population- and electronic-based instrument implemented for the retrospective and prospective collection of real-world data. The collection of data is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain evidence drawn from routine patients’ management. The collection of standardized data is thought to bring knowledge about real-life clinical research and potentially communicate with other existing and future Registries dedicated to Still’s disease. Moreover, it has been conceived to be flexible enough to easily change according to future scientific acquisitions. Results: Starting from June 30th to February 7th, 2022, 110 Centers from 23 Countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 4449 fields organized into 14 instruments, including patient’s demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. Conclusions: This international Registry for patients with Still’s disease will allow a robust clinical research through collection of standardized data, international consultation, dissemination of knowledge, and implementation of observational studies based on wide cohorts of patients followed-up for very long periods. Solid evidence drawn from “real-life” data represents the ultimate goal of t

Published
2022

45. OP0044 CYTOKINE PROFILE, HYPERFERRITINEMIA, AND MULTI-VISCERAL INVOLVEMENT CHARACTERISE MACROPHAGE ACTIVATION SYNDROME COMPLICATING ADULT ONSET STILL’S DISEASE. RESULTS FROM A MULTIDIMENSIONAL EVALUATION

Author

Ruscitti, P., primary, Ursini, F., additional, Berardicurti, O., additional, Masedu, F., additional, Bozzalla Cassione, E., additional, Naldi, S., additional, DI Cola, I., additional, DI Muzio, C., additional, De Stefano, L., additional, DI Nino, E., additional, Sensini, F., additional, Navarini, L., additional, Vomero, M., additional, Bugatti, S., additional, Valenti, M., additional, Mariani, E., additional, Iagnocco, A., additional, Montecucco, C., additional, Giacomelli, R., additional, and Cipriani, P., additional

Published
2022
Full Text
View/download PDF

47. AB0261 CARDIOMETABOLIC COMORBIDITIES MAY IDENTIFY A MORE SEVERE SUBSET OF RHEUMATOID ARTHRITIS, RESULTS FROM A “REAL-LIFE” STUDY

Author

Ruscitti, P., primary, Conforti, A., additional, DI Muzio, C., additional, Currado, D., additional, Navarini, L., additional, Pavlych, V., additional, DI Cola, I., additional, Sensini, F., additional, Biaggi, A., additional, DI Donato, S., additional, Marino, A., additional, Lorusso, S., additional, Ursini, F., additional, Giacomelli, R., additional, and Cipriani, P., additional

Published
2022
Full Text
View/download PDF

48. POS1337 ADULT-ONSET STILL’S DISEASE WITH ELDERLY ONSET, RESULTS FROM A MULTICENTRE STUDY AND ASSESSMENT OF AGE INFLUENCE ON CLINICAL FEATURES AND DISEASE OUTCOMES.

Author

DI Cola, I., primary, DI Muzio, C., additional, Conforti, A., additional, Iacono, D., additional, Pantano, I., additional, Rozza, G., additional, Rossi, S., additional, De Stefano, L., additional, Vitale, A., additional, Caso, F., additional, Costa, L., additional, Prete, M., additional, Navarini, L., additional, Sensini, F., additional, Iagnocco, A., additional, Atzeni, F., additional, Guggino, G., additional, Perosa, F., additional, Cantarini, L., additional, Frediani, B., additional, Bugatti, S., additional, Montecucco, C., additional, Ciccia, F., additional, Giacomelli, R., additional, Cipriani, P., additional, and Ruscitti, P., additional

Published
2022
Full Text
View/download PDF

49. AB1182 SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS) AND INFLAMMATORY NETWORKS IN PATIENTS AFFECTED BY ADULT ONSET STILL’S DISEASE (AOSD) AND COVID-19

Author

Navarini, L., primary, Vomero, M., additional, Berardiucrti, O., additional, Currado, D., additional, Marino, A., additional, Biaggi, A., additional, DI Donato, S., additional, Ursini, F., additional, Ruscitti, P., additional, Meliconi, R., additional, Cipriani, P., additional, Iagnocco, A., additional, Afeltra, A., additional, and Giacomelli, R., additional

Published
2022
Full Text
View/download PDF

50. POS1267 LONG-TERM SURVEY STUDY OF THE IMPACT OF COVID-19 ON SYSTEMIC AUTOIMMUNE DISEASES. LOW DEATH RATE DESPITE THE INCREASED PREVALENCE OF SYMPTOMATIC INFECTION. ROLE OF PRE-EXISTING INTERSTITIAL LUNG DISEASE AND ONGOING TREATMENTS.

Author

Ferri, C., primary, Raimondo, V., additional, Gragnani, L., additional, Giuggioli, D., additional, Dagna, L., additional, Tavoni, A., additional, Ursini, F., additional, L’andolina, M., additional, Caso, F., additional, Ruscitti, P., additional, Caminiti, M., additional, Foti, R., additional, Riccieri, V., additional, Guiducci, S., additional, Pellegrini, R., additional, Zanatta, E., additional, Varcasia, G., additional, Olivo, D., additional, Gigliotti, P., additional, Cuomo, G., additional, Murdaca, G., additional, Cecchetti, R., additional, De Angelis, R., additional, Romeo, N., additional, Ingegnoli, F., additional, Cozzi, F., additional, Codullo, V., additional, Cavazzana, I., additional, Colaci, M., additional, Abignano, G., additional, De Santis, M., additional, Lubrano, E., additional, Fusaro, E., additional, Spinella, A., additional, Lumetti, F., additional, De Luca, G., additional, Bellando Randone, S., additional, Visalli, E., additional, Dal Bosco, Y., additional, Amato, G., additional, Giannini, D., additional, Bilia, S., additional, Masini, F., additional, Pellegrino, G., additional, Pigatto, E., additional, Generali, E., additional, Pagano Mariano, G., additional, Pettiti, G., additional, Zanframundo, G., additional, Brittelli, R., additional, Aiello, V., additional, Caminiti, R., additional, Scorpiniti, D., additional, Ferrari, T., additional, Campochiaro, C., additional, Brusi, V., additional, Fredi, M., additional, Moschetti, L., additional, Cacciapaglia, F., additional, Ferrari, S. M., additional, DI Cola, I., additional, Vadacca, M., additional, Lorusso, S., additional, Monti, M., additional, Lorini, S., additional, Paparo, S. R., additional, Ragusa, F., additional, Elia, G., additional, Mazzi, V., additional, Aprile, M. L., additional, Tasso, M., additional, Miccoli, M., additional, Bosello, S. L., additional, D’angelo, S., additional, Doria, A., additional, Franceschini, F., additional, Meliconi, R., additional, Matucci-Cerinic, M., additional, Iannone, F., additional, Giacomelli, R., additional, Salvarani, C., additional, Zignego, A. L., additional, Fallahi, P., additional, and Antonelli, A., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results